Antithymocyte Globulin Inhibits CD8+ T Cell Effector Functions via the Paracrine Induction of PDL-1 on Monocytes

Cells. 2023 Jan 20;12(3):382. doi: 10.3390/cells12030382.

Abstract

Background: Antithymocyte globulins (ATG) are T cell-depleting antibodies used in solid organ transplantation for induction therapy in sensitized patients with a high risk of graft rejection. Previously described effects besides the depletion of T cells have suggested additional modes of action and identified further cellular targets.

Methods: We examined the transcriptional changes arising in immune cells from human blood after ex vivo stimulation with ATG at the single-cell level to uncover additional mechanisms by which ATG regulates T cell activity and effector functions.

Findings: Analysis of the paracrine factors present in the plasma of ATG-treated whole blood revealed high levels of chemokines and cytokines, including interferon-γ (IFN-γ). Furthermore, we identified an increase in the surface expression of the programmed death ligand 1 (PDL-1) on monocytes mediated by the released paracrine factors. In addition, we showed that this induction is dependent on the activation of JAK/STAT signaling via the binding of IFN-γ to interferon-γ receptor 1 (IFN-γR1). Lastly, we demonstrated that the modulation of the immune regulatory axis of programmed cell death protein 1 (PD1) on activated CD8+ T cells with PDL-1 found on monocytes mediated by ATG potently inhibits effector functions including the proliferation and granzyme B release of activated T cells.

Interpretation: Together, our findings represent a novel mode of action by which ATG exerts its immunosuppressive effects.

Keywords: T cell activation; antithymocyte globulin; inhibitory co-stimulation; single-cell RNA sequencing.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antilymphocyte Serum* / pharmacology
  • CD8-Positive T-Lymphocytes*
  • Humans
  • Interferon-gamma / metabolism
  • Monocytes / metabolism

Substances

  • Antilymphocyte Serum
  • CD274 protein, human
  • Interferon-gamma

Grants and funding

This study was funded by the Vienna Business Agency Grant (No. 852748 (HJA)), Vienna Business Agency Grant (No. 862068 (HJA)) and The Austrian Research Promotion Agency Grant (No. 2343727 (HJA)).